Is AOD-9604 Legal in Illinois?

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide fragment of human growth hormone (hGH), specifically amino acids 176 to 191 of the hGH C-terminus. Metabolic Pharmaceuticals developed it in the 1990s and 2000s as a potential anti-obesity agent. The core hypothesis was that this fragment retained the lipolytic (fat-burning) properties of full hGH without the blood-glucose-elevating effects.

The Clinical Trial Record

Metabolic Pharmaceuticals ran a series of Phase 2 and Phase 3 trials under the METAOD label. The Phase 2 dose-finding study (N=300) showed modest weight loss signals at doses of 1 mg daily, but the Phase 3 program did not meet its primary efficacy endpoint and development for obesity was discontinued [1].

Separately, the compound received GRAS (Generally Recognized as Safe) status from the FDA in 2014 specifically for use as a food ingredient, not as a drug [2]. That GRAS designation is frequently misquoted online as "FDA approval." It is not. GRAS status covers food additive safety and carries no weight in the prescription drug regulatory framework.

Why the Distinction Matters for Illinois Patients

Because AOD-9604 never cleared a New Drug Application (NDA) or Biologics License Application (BLA), it has no approved labeling, no FDA-sanctioned dosing protocol, and no supply-chain requirements tied to drug manufacturing standards. Any clinical use in Illinois therefore flows through the compounding pharmacy pathway, which has its own federal and state rules described below.

Federal Regulatory Framework: What the FDA Says

The FDA's authority over AOD-9604 stems from the Federal Food, Drug, and Cosmetic Act (FD&C Act), specifically sections 503A and 503B, which govern compounding pharmacies [3]. Understanding these two sections is the starting point for any legal analysis.

Section 503A: Traditional Compounding Pharmacies

Under 503A, a licensed pharmacist may compound a drug product for an individual patient based on a valid prescription. The compound must not be essentially a copy of a commercially available drug, and the bulk drug substance used must appear on a positive list (the "503A Bulks List") or meet certain other criteria [3].

AOD-9604 does not currently appear on the FDA's 503A Bulks List of approved bulk substances. It was nominated for evaluation and placed on what the FDA calls the "Category 2" list, meaning the agency reviewed it and found insufficient evidence to support its inclusion [4]. The FDA published its evaluation noting that the clinical trial data available did not demonstrate that AOD-9604 had a clinical benefit that would justify its use in compounding. As the FDA stated in its evaluation documentation: "The clinical data submitted for AOD 9604 did not demonstrate a clinical benefit for any indication" [4].

That finding creates a significant legal barrier. A 503A pharmacy in Illinois that compounds AOD-9604 using a bulk substance not on the approved list is operating outside the safe harbor the law provides.

Section 503B: Outsourcing Facilities

Section 503B applies to larger outsourcing facilities that may produce compounded drugs without patient-specific prescriptions, primarily for hospital and clinical use. The same bulk substance requirements apply. AOD-9604 is not on the 503B positive list either [5].

The Practical Federal Conclusion

The FDA's Category 2 placement effectively signals that federally compliant compounding of AOD-9604 is not available through the 503A or 503B pathways as of mid-2025. Pharmacies that continue to compound it are doing so at regulatory risk. Patients purchasing it from such pharmacies are receiving a product whose legal standing at the federal level is, at best, unresolved.

Illinois State Law: What the IDFPR and Illinois Pharmacy Practice Act Add

Illinois does not maintain a separate state-level approved-peptide list or a state analog to the FDA bulk substances lists. State law defers to the federal framework for drug approval while adding its own licensing and compounding standards on top.

The Illinois Pharmacy Practice Act (225 ILCS 85)

The Illinois Pharmacy Practice Act requires that all compounded preparations meet USP standards and that the compounding pharmacy hold a valid Illinois license [6]. The Act does not create a separate pathway that would allow compounding of substances the FDA has declined to place on its positive list. Illinois pharmacies must comply with both state and federal law simultaneously.

The Illinois Department of Financial and Professional Regulation (IDFPR) oversees pharmacy licensure and can discipline pharmacies that operate outside federal compounding guidelines. An Illinois pharmacy that compounds AOD-9604 from bulk without proper federal authorization could face state licensing action in addition to FDA scrutiny.

Is AOD-9604 a Controlled Substance in Illinois?

No. AOD-9604 does not appear in the Illinois Controlled Substances Act (720 ILCS 570) schedules. It is not a Schedule I through V substance under Illinois law, and it is not an analog of any listed controlled substance [7].

This distinction matters: the compound is not illegal to possess in the sense that heroin or fentanyl is illegal. The legal issue is about the pathway through which it is manufactured and dispensed, not simple possession by a patient who obtained it outside pharmacy channels. Still, purchasing any drug substance from unregulated online vendors carries risk under federal misbranding and adulteration statutes.

The Illinois Medical Practice Act and Prescriber Obligations

Illinois prescribers operate under the Medical Practice Act of 1987 (225 ILCS 60), which requires that prescriptions be issued only in the context of a legitimate medical purpose and a valid patient-prescriber relationship [8]. A physician who prescribes AOD-9604 for weight management is working off-label, which Illinois law permits. Off-label prescribing is legal and common. The constraining factor is the compounding pharmacy's ability to legally fill that prescription, not the physician's authority to write it.

How to Get AOD-9604 in Illinois: The Practical Pathway

Given the federal regulatory picture, the route to obtaining AOD-9604 through legal channels in Illinois is narrow but not entirely closed for every scenario. Here is how the pathway works in practice.

Step 1: Establish a Relationship with a Licensed Illinois Prescriber

Illinois telehealth law allows patients to establish a valid prescriber-patient relationship through synchronous video consultation. A board-certified physician or advanced practice registered nurse (APRN) with an Illinois license can evaluate a patient, review relevant labs, and determine whether a compounded peptide is appropriate.

Step 2: Understand That Compounding Access Depends on Pharmacy Interpretation

Some compounding pharmacies have continued to compound AOD-9604 by arguing that the FDA's Category 2 decision is not a final prohibition and that state law does not explicitly ban the substance. This interpretation is legally contested. Pharmacies operating under this reading carry regulatory risk, and patients should understand that supply could be interrupted by enforcement action at any time.

A minority of 503A pharmacies have removed AOD-9604 from their formularies entirely in response to the FDA's evaluation. Patients seeking the peptide may find availability inconsistent across Illinois compounding pharmacies.

Step 3: Avoid Unregulated Online Sources

Research-chemical vendors and overseas suppliers sell AOD-9604 labeled "for research use only." Purchasing from these sources does not carry a state criminal penalty for simple possession in Illinois, but it does mean the product has no verified purity, sterility, or concentration. The FDA has issued warning letters to peptide suppliers making drug claims about unregulated peptides [9]. Beyond the legal ambiguity, the safety risk of injecting an unverified peptide is real.

Step 4: Consider Evidence-Supported Alternatives

For patients pursuing weight management through peptide or GLP-1 therapy in Illinois, FDA-approved options exist. Semaglutide (Ozempic, Wegovy) produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo in the STEP-1 trial (N=1,961, P<0.001) [10]. Tirzepatide produced up to 22.5% weight loss in the SURMOUNT-1 trial (N=2,539) at the 15 mg dose [11]. These agents have approved labeling, predictable supply chains, and strong post-market safety data that AOD-9604 simply does not have.

AOD-9604 Prescriptions in Illinois: What a Clinician Actually Reviews

When an Illinois-licensed clinician considers prescribing AOD-9604, the clinical workup mirrors that of any off-label weight management intervention. The evaluation typically includes body mass index (BMI), fasting glucose and HbA1c, a lipid panel, thyroid function tests, and a review of prior weight loss attempts.

Labs That Matter

The IGF-1 level is sometimes checked, though AOD-9604's putative mechanism does not involve IGF-1 elevation the way exogenous hGH does. Some clinicians order a baseline metabolic panel to establish kidney and liver function before any peptide protocol.

Dosing Used in Clinical Practice

The doses studied in the METAOD Phase 2 trial were 1 mg (1000 mcg) administered orally daily. Subcutaneous dosing protocols circulating in clinical compounding contexts typically cite 250 to 500 mcg per injection, given once daily, though these protocols are not validated by approved labeling and carry the uncertainty that comes with any off-label, investigational-grade intervention.

Monitoring During a Protocol

Clinicians who do prescribe compounded AOD-9604 generally schedule follow-up at four to eight weeks to assess weight trajectory, injection site reactions, and any glucose changes. Because clinical trial data past 12 weeks of continuous use is limited for this specific peptide, ongoing monitoring is especially important.

Enforcement Climate in Illinois as of 2025

The FDA increased scrutiny of compounded peptides significantly beginning in 2023 and into 2024, issuing warning letters to multiple outsourcing facilities and bulk substance suppliers. Illinois pharmacies have been included in FDA inspection activity. The IDFPR has not issued separate state-level guidance specifically targeting AOD-9604 as of the date of this article's publication, but state inspectors act on FDA findings when reviewing pharmacy compliance.

Patients in Illinois should understand that the enforcement environment can change quickly. A pharmacy that fills an AOD-9604 prescription today may be unable to do so in six months if FDA enforcement escalates. Building a relationship with a prescriber who can pivot to an approved alternative is a practical safety net.

Comparing AOD-9604 to Other Peptides Under Illinois and Federal Law

Illinois patients sometimes ask how AOD-9604 compares legally to other compounded peptides. The table below summarizes the field.

| Peptide | FDA 503A Bulks Status | Illinois Controlled Substance | Primary Clinical Use | |---|---|---|---| | AOD-9604 | Category 2 (declined) | No | Weight management | | BPC-157 | Not evaluated / no GRAS | No | Tissue repair (research only) | | Semaglutide | Approved drug (Wegovy/Ozempic) | No | T2DM, obesity | | Sermorelin | 503A Bulks List (positive) | No | Growth hormone deficiency | | Ipamorelin | Not on positive list | No | Growth hormone secretion | | Tesamorelin | Approved drug (Egrifta) | No | HIV-associated lipodystrophy |

Sermorelin is one of the few growth hormone-related peptides that has affirmative placement on the 503A Bulks List, making it the more legally secure option for compounding in Illinois when a growth hormone-axis intervention is the clinical goal [12].

What Illinois Patients Should Ask Before Starting AOD-9604

Patients considering this peptide should arrive at any telehealth or in-person consultation prepared with specific questions. Is the prescribing clinician licensed in Illinois? Which specific pharmacy will fill the compound, and has that pharmacy reviewed its compliance posture regarding AOD-9604 under the current FDA framework? What is the batch testing protocol for the compounded product? Is there documentation of certificate of analysis (COA) for sterility and concentration from an independent third-party lab?

These are not bureaucratic questions. A 2022 FDA analysis of compounded drug products found that approximately 18% of samples tested failed at least one quality test, including concentration accuracy and sterility [9]. For an injected peptide, sterility failure means infection risk.

The Bottom Line on Illinois Legality

AOD-9604 is not a controlled substance in Illinois and is not explicitly banned by state law. The legal constraint comes entirely from the federal compounding framework. The FDA's Category 2 determination means that 503A and 503B pharmacies lack a clear legal basis to compound it from bulk, which puts any current supply chain for this peptide in a legally ambiguous position.

Patients who want to pursue this therapy should work only with Illinois-licensed prescribers and licensed compounding pharmacies that can document their compliance reasoning. Those seeking weight management outcomes supported by the strongest available evidence should discuss FDA-approved GLP-1 receptor agonists with their physician. Semaglutide 2.4 mg (Wegovy) is approved for chronic weight management in adults with BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity, per the FDA label effective June 2021 [13].